Next-gen Nanotech Drug Delivery Platform will use the funds to expand sales in newmarkets and increase product research and development.
Belfast, Northern Ireland — SiSaf, the next-gen silicon nanotechnology drug deliverycompany, announced today a Series A investment of $3.5 million led by prominent Asianand American venture capital investors Vickers Venture Partners and EXEN Capital. Thefinancing will be used to fund sales expansion in new markets and increase product researchand development. Dr Elkhalil Binebine, Vice Chairman at Vickers, and Eric Attias, ManagingPartner at EXEN Capital, will join SiSaf’s board of directors. Invest Northern Ireland, aninvestor in earlier rounds, also followed on in this round.
“Sisaf’s technology changes the game in drug formulation, by enabling the packaging anddelivery of drugs that cannot otherwise be formulated,” said Dr ElKhalil Binebine. “We see anew wave of innovative medicines emerging from recent breakthroughs in the life sciences.However, getting these medicines to the right place in the body and at the right doseremains hugely challenging. The groundbreaking nanoparticle drug delivery technology thatSuzanne and the team have developed enables safe and effective targeting of these newdrugs, as well as making old drugs even more useful by allowing for controlled release andlower doses. We’re excited to be working together with them to build a world-leading drugdelivery company.”
Suzanne Saffie-Siebert, Founder and Chairwoman of SiSaf, commented: “We’re delighted tohave Vickers Venture Partners and Exen Capital as strategic investors,”SiSaf is at a veryexciting point in its history. After years of R&D, our technology is ready for fullcommercialization. Our drug delivery platform has matured into a genuine game changerand its potential applications are massive. Vickers and Exen have a great track record ofbuilding companies and their global network and expertise in the life science sector will bekey to accelerating SiSaf’s growth.”